Enveric Biosciences, Inc.
NCM: ENVBLive Quote
About Enveric Biosciences, Inc.
Healthcare
Biotechnology
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Enveric Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -304.0%, which indicates that capital utilization is currently under pressure.
At a current price of $1.96, ENVB currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $1.75 - $17.84).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$5.89M
Trailing P/E
--
Forward P/E
-1.39
Beta (5Y)
0.33
52W High
$17.84
52W Low
$1.75
Avg Volume
366K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App